drugset / Trial / NCT04460456
A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A first-in-human (FIH) study using SBT6050 and SBT6050 in combination with PD-1 inhibitors in HER2 expressing or amplified advanced malignancies
Timeline
- Start
- 2020-07-27
- Primary completion
- 2022-12
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PERTUZUMAB ZUVOTOLIMOD | Unknown | — | — |
| Background | Cemiplimab | Monoclonal antibody | 350 mg | Intravenous |
| Background | Pembrolizumab | Monoclonal antibody | 400 mg | Intravenous |